"I also like the implication from the PR that once phase I studies are completed in 1H07, an aggressive phase II development program on anti-VEGFR2 will be implemented. Full ownership. Huge market potential."
Take in the Merrill Healthcare Conf presentation today. It can be found on IMCL's website.
ER specifically alluded to this and essentially referred to Avastin by name.